Anzeige
Mehr »
Donnerstag, 23.10.2025 - Börsentäglich über 12.000 News
Das Comeback des Goldrauschs - diesmal ausgelöst durch eine Währungskrise
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A2JP7J | ISIN: DK0061030574 | Ticker-Symbol: EP2
Frankfurt
23.10.25 | 08:01
1,720 Euro
0,00 % 0,000
Branche
Biotechnologie
Aktienmarkt
Sonstige
1-Jahres-Chart
VIROGATES A/S Chart 1 Jahr
5-Tage-Chart
VIROGATES A/S 5-Tage-Chart

Aktuelle News zur VIROGATES Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
08.10.ViroGates A/S - Observation status103Nasdaq Copenhagen has given the company below observation status: ISIN DK0061030574 Symbol VIRO ViroGates A/S has been given observation status, as the company has announced that suPAR...
► Artikel lesen
08.10.ViroGates A/S: suPAR Remedy, LLC announces public tender offer to the shareholders of ViroGates A/S at a 40% premium99NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR TO ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF SUCH JURISDICTION Company...
► Artikel lesen
VIROGATES Aktie jetzt für 0€ handeln
21.08.ViroGates A/S: ViroGates announces its Half-Year Report for H1 202595Company Announcement no. 10/2025 (August 21, 2025) Revenue ending 18% below H1 2024, operating loss reduced by 26%, and proof of concept achieved for suPARnostic® POC+ in longevity BIRKERØD, DENMARK...
► Artikel lesen
16.06.ViroGates A/S: ViroGates and GENSPEED achieve proof of concept for their suPARnostic POC+ targeted at the Longevity Testing Market178Company Announcement no. 9/2025 (June 16, 2025) BIRKERØD, DENMARK - ViroGates A/S ("ViroGates" or the "Company"), a medical technology company developing blood tests for measuring chronic inflammation...
► Artikel lesen
21.05.ViroGates A/S: Resolutions from the Extraordinary General Meeting of ViroGates A/S134Company Announcement no. 8/2025 (May 21, 2025) BIRKERØD, DENMARK - ViroGates A/S ("ViroGates" or the "Company"), a medical technology company developing blood tests for measuring chronic inflammation...
► Artikel lesen
01.05.ViroGates A/S: ViroGates announces its Q1 report for 202598Company Announcement no. 6/2025 (May 01, 2025) Revenue comparable to the same period last year, operating expenses reduced by 33%, and an amended agreement with Sobi BIRKERØD, DENMARK - ViroGates A/S...
► Artikel lesen
20.03.ViroGates A/S: ViroGates announces its Annual Report 2024187Company Announcement no. 3/2025 (March 20, 2025) Revenue declines by 12 % compared to last year as ViroGates continues the transition into the health- and longevity segment and fosters strategic partnerships BIRKERØD...
► Artikel lesen
07.11.24ViroGates A/S: ViroGates announces its Interim Report for Q1-Q3 2024: Revenues are disappointing, but strategic refocusing will pave the way for future growth258Company Announcement no. 9/2024 (November 07, 2024) BIRKERØD, DENMARK - ViroGates A/S ("ViroGates" or the "Company"), a medical technology company developing blood tests for the measurement of chronic...
► Artikel lesen
06.11.24First North Denmark: ViroGates A/S - increase456New shares in ViroGates A/S will be admitted to trading on Nasdaq First North Growth Market Denmark as per 8 November 2024. New shares are issued due to a directed issue of new shares. Name: ...
► Artikel lesen
9 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1